Noah Stansfield

Full data readouts have not been shared.

Sensorion indicated it is still on track to submit a clinical trial application in the first half of next year.

There was no significant difference in OS and CR rate for patients based on household poverty and neighborhood opportunity.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

In preclinical research, TN-401 was shown to significantly increase the lifespan of PKP2-knock-out mice.

The study has now dosed 8 patients in total.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Omidubicel’s BLA was originally accepted for priority review in August of this year.

Statistically significant improvements in cognitive development were only seen in the cohort of patients younger than 30 months.

The gene therapy was approved in the European Union earlier this year.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

ExCellThera is in the process of the expanding the studies into new trial sites in the United States and Europe.

AFNT-111 showed anti-tumor activity in NSG mouse models of breast cancer, pancreatic cancer, and colon cancer.

KYV-101 is an autologous version of a CD19-directed fully human CAR-T construct.

Among the 16 patients treated in the trial, 5 showed stable disease after treatment.

The data included an IRC-assessed ORR of 31.4%.

The patient’s ECOG performance status remained at 0 from screening through the rest of trial participation.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Several of the first cohort patients have had their Cell Pouch implants for over 3 years and no patients have elected to have their implants removed.

Among the trial’s high dose cohort, 80% of patients did not require supplemental injections for over 2 years.

Preclinical research in an OTOF-knockout mouse model demonstrated reversal of deafness.

The platform is capable of producing lentiviral vectors for preclinical, clinical, and commercial scales with high titers ranging from 1x10^8 TU/ml to 1x10^9 TU/ml.

AlloStem will be evaluated in the CELZ-201 clinical trial for patients with newly diagnosed type 1 diabetes.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

MT-101 is designed for quick delivery to patients with a vein-to-vein time of 8 days.

TIDAL-01 will be evaluated in patients with advanced or metastatic breast carcinoma, colorectal adenocarcinoma, or uveal melanoma.

MRI revealed that participants who achieved sustained or confirmed disability improvement showed significantly less ventricular enlargement at 12 months.

AVR-RD-02 also received ILAP designation in the UK earlier this month.

RZ-001 previously received IND clearance from the South Korean Ministry of Food and Drug Safety in June.

The decision comes after strategic uncertainty regarding a review of preliminary clinical data from GSK’s lete-cel product candidate trial.